Alzheimer's Sleep Loss Finally Traced to Brain Immune Cells — Not Amyloid Plaques

For decades, the prevailing assumption was that the sticky amyloid plaques clogging the brains of Alzheimer's patients were also responsible for the severe sleep disruption that affects nearly every person with the disease. A new study turns that assumption on its head.

Researchers at the University of Kentucky have discovered that the real culprit behind Alzheimer's-related sleep loss is not amyloid at all — it is the brain's own immune cells, called microglia, becoming chronically overactive and disrupting the sleep-regulating circuits. When the team silenced these overactive microglia using a targeted drug, Alzheimer's mouse models regained roughly two hours of nightly sleep — a significant improvement that brought their sleep patterns closer to healthy levels.

The finding is a fundamental shift in how scientists understand the relationship between Alzheimer's pathology and sleep. Sleep disruption in Alzheimer's often begins decades before memory loss appears, and treating it as a symptom of amyloid buildup has yielded limited results. By targeting microglia instead, researchers may have opened a completely new therapeutic avenue that addresses sleep loss directly, without needing to clear the brain of amyloid plaques.

The study, published in Alzheimer's & Dementia, builds on growing evidence that the immune system plays a far more active role in Alzheimer's disease progression than previously recognized. If the mechanism holds in human trials, it could lead to the first treatments specifically aimed at restoring sleep in Alzheimer's patients — improving quality of life for millions of families worldwide.